MediWound (NASDAQ:MDWD – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
Analyst Recommendations
This is a summary of current recommendations for MediWound and Upstream Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
MediWound presently has a consensus price target of $33.00, indicating a potential upside of 133.88%. Upstream Bio has a consensus price target of $26.67, indicating a potential upside of 688.95%. Given Upstream Bio’s higher possible upside, analysts clearly believe Upstream Bio is more favorable than MediWound.
Valuation & Earnings
This table compares MediWound and Upstream Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $16.96 million | 10.82 | -$23.88 million | ($1.80) | -7.84 |
| Upstream Bio | $2.85 million | 64.96 | -$143.44 million | ($2.90) | -1.17 |
MediWound has higher revenue and earnings than Upstream Bio. MediWound is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
MediWound has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Insider and Institutional Ownership
46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 16.5% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares MediWound and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -170.10% | -47.24% | -24.27% |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
Summary
MediWound beats Upstream Bio on 8 of the 13 factors compared between the two stocks.
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.
About Upstream Bio
Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues. Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
